课题基金 / 基金详情

Novel small molecule library development

Novel small molecule library development
新型小分子库开发
批准号:
10007528
负责人:
Craig Thomas
金额:
$29.95万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Craig Thomas的其他基金

相似基金

相关文献

中文摘要
翻译
选择、获取和使用高质量的小分子文库进行筛选是药物发现和化学生物学计划的一个重要方面。随着研究人员对小分子对特定生物靶点、过程和环境的适应性有了更大的了解,筛选文库继续进化。围绕任何给定的小分子文库的组成的决定受到许多变量的影响,对最佳实践的看法各不相同。任何收集的适合性都取决于预先过滤,以避免有问题的化合物,评估适当的物理化学性质,安装理想的结构独特性水平,并确定所需的分子复杂性程度。这些标准正在不断地评估和修订,因为学术和行业组织正在寻找能够从他们的筛查组合中产生不断改进的结果的集合。实际问题,包括成本、化合物管理、筛选的复杂性和检测目标也在文库成分的选择中发挥着重要作用。我们的团队继续开发新的文库,包括机械询问板或MIPE,以及用于单一试剂和联合筛选平台的新的稳定代谢物库。这些文库是研究多种疾病模型的重要工具。
英文摘要
The selection, acquisition and use of high-quality, small-molecule libraries for screening are an essential aspect of drug discovery and chemical biology programs. Screening libraries continue to evolve as researchers gain a greater appreciation of the suitability of small molecules for specific biological targets, processes and environments. The decisions surrounding the make-up of any given small molecule library is informed by a multitude of variables, and opinions vary on best-practices. The fitness of any collection relies upon upfront filtering to avoid problematic compounds, assess appropriate physicochemical properties, install the ideal level of structural uniqueness and determine the desired extent of molecular complexity. These criteria are under constant evaluation and revision as academic and industrial organizations seek out collections that yield ever-improving results from their screening portfolios. Practical questions including cost, compound management, screening sophistication and assay objective also play a significant role in the choice of library composition. Our team continues to develop novel libraries including the Mechanism Interrogation Plate or MIPE and a novel stable metabolite library for use in both single agent and combination screening platforms. These libraries represent important tools for studying multiple models of disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a novel aIIbB3 receptor antagonist for pre-hospital myocardial infarction therapy
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor
The development of multikinase inhibitors for the treatment of selected cancers
Development of a first-in-class O-GlcNAc transferase (OGT) inhibitor
海外基金